Trial reportEuropean heart journal2021
The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context.
Trial report in European heart journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.The Cochrane database of systematic reviews · 2021Pooled it
- Prognostic Role of High-Sensitivity C-Reactive Protein/Albumin Ratio in Heart Failure Patients.Biomedicines · 2026Article
- Review
- Beyond quadruple therapy: the potential roles for ivabradine, vericiguat, and omecamtiv mecarbil in the therapeutic armamentarium.Heart failure reviews · 2024Review
- Elucidating the cardioprotective mechanisms of sodium-glucose cotransporter-2 inhibitors beyond glycemic control.World journal of diabetes · 2024Article
- Association Between Diabetes, Chronic Kidney Disease, and Outcomes in People With Heart Failure From Asia.JACC. Asia · 2023Article
- The year in cardiovascular medicine 2021: heart failure and cardiomyopathies.European heart journal · 2022Article
- Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2021Review
- Targeting Adrenergic Receptors in Metabolic Therapies for Heart Failure.International journal of molecular sciences · 2021Review
- SGLT2-inhibitors; more than just glycosuria and diuresis.Heart failure reviews · 2021Review
- Longevity genes, cardiac ageing, and the pathogenesis of cardiomyopathy: implications for understanding the effects of current and future treatments for heart failure.European heart journal · 2020Article
- Molecular, Cellular, and Clinical Evidence That Sodium-Glucose Cotransporter 2 Inhibitors Act as Neurohormonal Antagonists When Used for the Treatment of Chronic Heart Failure.Journal of the American Heart Association · 2020Review
- Basic Mechanisms of Diabetic Heart Disease.Circulation research · 2020Review
- Heart Failure With Type 2 Diabetes Mellitus: Association Between Antihyperglycemic Agents, Glycemic Control, and Ejection Fraction.Frontiers in endocrinology · 2020Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.